The purpose of this study is to evaluate how well maribavir works in treating cytomegalovirus infection in these patients and to assess what side effects might lead to stopping the treatment. The study will measure success by checking whether the amount of virus in the blood drops to very low levels that cannot be easily measured after eight weeks of treatment. The medication is taken by mouth in the form of film-coated tablets, with a maximum daily dose of 800 milligrams, and treatment can continue for up to twelve weeks.

During the study, patients will have regular blood tests to measure the amount of virus in their blood and to monitor for any side effects. The study will track how many patients respond to the treatment within eight weeks and will also follow patients for an additional eight weeks after they stop taking the medication to see if the virus returns. Some patients who show partial improvement at eight weeks may continue treatment for up to twelve weeks to see if they achieve a better response. The study will also record any side effects that occur during treatment, particularly those that are serious enough to require stopping the medication.

The purpose of the study is to compare two different approaches to preventing CMV infection in kidney transplant recipients. One approach is called immune-guided prophylaxis, which involves using the body’s immune response to guide treatment. The other approach is preemptive therapy, which means starting treatment as soon as early signs of infection appear. The study will monitor the effectiveness and safety of these approaches over time.

Participants in the study will be observed for up to 12 months after their kidney transplant. The study will look at how many patients develop CMV disease and how many experience a condition called neutropenia, which is a low level of a type of white blood cell that helps fight infections. The study will also track the number of days patients take Valganciclovir and any side effects that occur. The goal is to determine which approach provides better outcomes for patients, with a focus on preventing CMV disease without causing neutropenia.

The treatment being studied involves the use of advanced cellular immunotherapy, specifically with Cytolytic T Lymphocytes (CTLs). These are special immune cells that can target and destroy virus-infected cells. The purpose of the study is to evaluate how effective this treatment is in reducing the occurrence of CMV infection within the first 100 days after the transplant. This is compared to historical data from similar patients who did not receive this treatment.

Participants in the study will receive the CTL treatment through an injection. The study will monitor the incidence of CMV infection and assess the need for further CMV treatment. It will also evaluate the presence of specific immune cells that remember the CMV virus, known as CMV-specific memory T lymphocytes. The study aims to provide valuable insights into the potential benefits of using CTLs for preventing CMV infections in this patient group.

The purpose of the study is to determine if Letermovir can increase the chances of a newborn having a negative CMV test at birth compared to Valaciclovir. The study will involve pregnant women who have a CMV infection in the first trimester and are carrying a fetus infected with CMV. Participants will receive either Letermovir or Valaciclovir, and the effects on the fetus and newborn will be monitored. The study will also look at the overall health and development of the newborns, as well as the safety and tolerance of the treatments for both mothers and babies.

Throughout the study, participants will undergo regular check-ups, including ultrasound scans and MRI to monitor the baby’s development. The study aims to provide valuable information on the effectiveness and safety of Letermovir as a treatment option for congenital CMV infection, potentially offering a new approach to managing this condition in the future.

Participants in the study will take Letermovir tablets orally. The study will monitor the occurrence of early CMV infections or disease during the period when participants are taking the medication. Additionally, the study will observe the rates of certain blood conditions, such as leukopenia (a decrease in white blood cells) and neutropenia (a decrease in a type of white blood cell called neutrophils), during the treatment period. The study will also look at the occurrence of late CMV infections after stopping the medication and the body’s immune response over time.

The study will continue for a set period, and participants will be closely monitored throughout. The goal is to gather information on the effectiveness of Letermovir in preventing CMV infections and to understand any potential side effects or resistance to the treatment. This research aims to improve the care and outcomes for heart transplant recipients who are at risk of CMV infections.

The purpose of the study is to explore how effective Letermovir is in preventing CMV infection in these specific transplant patients. Participants in the study will take Letermovir for a period of up to 14 weeks. During this time, the study will monitor the occurrence of CMV infection and any need for additional treatment. The study will also observe other health outcomes, such as the recovery of blood cells and any side effects related to the medication.

Throughout the study, participants will be regularly checked by healthcare professionals to ensure their safety and to gather information on how well Letermovir works in preventing CMV infection. The study aims to provide valuable insights into the use of Letermovir for CMV prevention in patients who have undergone an allogeneic stem cell transplant.

Participants in the study will be pregnant women who have recently developed CMV infection. The study will compare different doses of valacyclovir to understand which dose is most effective and safe. The medication will be given in the form of film-coated tablets, which are taken orally.

The study will follow the participants over a period of time to monitor the presence of CMV in the amniotic fluid, which surrounds the baby in the womb, and in the blood of both the mother and the fetus. The study will also look at the number of platelets, which are cells that help with blood clotting, in the fetus. Additionally, the study will track any side effects experienced by the participants. The goal is to gather information that will help in understanding how to best use valacyclovir to manage CMV infections during pregnancy.

The purpose of the study is to assess how well the T cell treatment works in clearing the viral infections in patients who have not responded to other treatments. Participants in the study will receive the T cell treatment through an infusion, which is a method of delivering the treatment directly into the bloodstream. The study will monitor the patients over a period of time to see if the viral infections are reduced or cleared and to observe any side effects or changes in health status.

Throughout the study, various health indicators will be checked, such as the presence of the virus in the blood and any symptoms related to the infections. The study will also look at the overall health and survival of the patients, as well as any potential side effects from the treatment. The goal is to determine if the T cell treatment can provide a new option for patients with these challenging viral infections after stem cell transplantation.

Participants in the study will receive either the combination of letermovir and valganciclovir or valganciclovir alone. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of up to 12 weeks, during which participants will have regular check-ups to monitor their health and the effectiveness of the treatment. The main goal is to see if the combination treatment can reduce the amount of CMV in the blood by the third week of treatment.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. Regular blood tests will be conducted to measure the levels of CMV and to ensure the safety and effectiveness of the treatment. The study aims to provide valuable information on the best treatment approach for managing CMV infections in kidney transplant patients, potentially improving outcomes for those affected by this condition.

The purpose of the study is to understand how effective these antiviral medications are in preventing CMV infection in patients who are otherwise healthy but have undergone significant heart surgery. Participants in the study will receive either the antiviral medication or a placebo, which is a substance with no active medication. The study will last for a period of 14 days, during which the patients will be monitored closely to assess their response to the treatment.

Throughout the study, various health markers will be measured to evaluate the patients’ immune response and the presence of the virus in their blood. The goal is to determine the best approach to prevent CMV infection in this specific group of patients, ultimately improving their recovery and reducing the risk of complications after heart surgery.

Participants in the study will take Valaciclovir orally. The study will monitor the health and safety of both the mother and the baby throughout the pregnancy and after birth. This includes regular check-ups using ultrasound and MRI scans to look for any signs of the virus being passed to the baby. Blood tests will also be conducted to ensure the safety of the mother and baby, checking important health indicators like liver and kidney function. After birth, the baby’s health will continue to be monitored, including hearing tests and developmental assessments up to five years of age.

The study aims to provide valuable information on whether Valaciclovir can help prevent the transmission of CMV during pregnancy, potentially offering a new way to protect babies from this infection. The trial is expected to continue until 2031, allowing researchers to gather comprehensive data on the long-term effects and benefits of using Valaciclovir in this context.

The purpose of the study is to evaluate how effective letermovir is in preventing CMV infections in lung transplant recipients over a period of 12 months. Participants in the study will take letermovir in the form of film-coated tablets, and their health will be monitored to see if the medication helps in reducing the incidence of CMV disease. The study will also look at other factors such as any side effects from the medications, including potential issues like leukopenia, which is a condition where the number of white blood cells is lower than normal, and renal toxicity, which refers to kidney problems that might arise from the treatment.

Throughout the study, researchers will keep track of any hospital readmissions due to CMV complications and any other infections that might occur. The study aims to provide valuable information on whether letermovir is a better option for preventing CMV infections in lung transplant patients compared to the standard treatment with valganciclovir.